RenovoRx surges on FDA approval for cancer treatment device

RenovoRx

07/09/2021 13:10

** Cancer biotech co's  RNXT.O  shares surge ~50% to $11.82
premarket, set to open at a record high since stock began
trading on Aug. 26
    ** RNXT says it received FDA approval for an updated design
of its proprietary RenovoCath Delivery System  urn:newsml:reuters.com:*:nPn5Ckc2Xa
    ** RenovoCath Delivery System is a catheter that helps
deliver cancer drugs directly to tumor sites
    ** More than 2.5 mln RNXT shares trade
    ** Up to Friday, stock down 12.3% than its IPO price of $9

 (Reporting by Ruhi Soni in Bengaluru;)
 ((Ruhi.Soni@thomsonreuters.com;))